CD BioGlyco, a leading biotechnology company specializing in glycobiology, is proud to announce its enhanced polysaccharide vaccine development services. Leveraging cutting-edge platforms and extensive expertise, CD BioGlyco is poised to support researchers and organizations in the development of safer, more effective vaccines against a wide range of infectious diseases.
Polysaccharides, complex carbohydrates found on the surface of many bacteria, represent excellent targets for vaccine development. Antibodies against polysaccharide epitopes can prevent invasive diseases caused by encapsulated bacteria. While polysaccharide vaccines have proven successful in stimulating B-cell responses, they do not generate long-lasting immunity due to the lack of T-cell involvement. This limitation has been overcome through the development of polysaccharide conjugate vaccines, where polysaccharides are covalently linked to carrier proteins, inducing T-cell-dependent responses.
CD BioGlyco offers comprehensive services for the development, production, and quality control of both polysaccharide and polysaccharide conjugate vaccines. The company’s scientists have established robust methods for polysaccharide purification, conjugation to protein carriers using various chemical techniques, and stringent quality control assessments. These include size exclusion chromatography (SEC), high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD), and nuclear magnetic resonance (NMR).
The company’s polysaccharide conjugation services are particularly valuable, as vaccines based on purified polysaccharides alone often yield insufficient immunity. By linking polysaccharides to macromolecular proteins, CD BioGlyco helps clients create vaccines that overcome this shortcoming and offer enhanced protection.
CD BioGlyco’s polysaccharide vaccine development services have far-reaching applications, from the creation of novel COVID-19 therapeutic agents to the reduction of incidence and mortality from invasive pneumococcal disease. The company’s commitment to simple operation, low costs, and high-quality products makes it an ideal partner for researchers seeking to advance the field of vaccine development.
As a recognized leader in the glycobiology industry, CD BioGlyco is dedicated to continuous improvement of its products and services. The company also provides tumor-associated carbohydrate vaccine development.
To know more about CD BioGlyco’s Polysaccharide Vaccine Development service, please visit https://www.bioglyco.com/polysaccharide-vaccine-development.html.
